

Louisiana Department of Health Bureau of Health Services Financing

#### MEMORANDUM

**DATE:** December 22, 2020

**TO:** All Louisiana Medicaid Prescribing Providers and Pharmacists

Jara Roblanc

**FROM:** Tara A. LeBlanc, Interim Medicaid Executive Director

**SUBJECT:** Louisiana Medicaid Pharmacy Point of Sale Clinical Updates and

Therapeutic Duplication for Agalsidase Beta (Fabrazyme®) and Migalastat

(Galafold®)

Effective January 1, 2021, the Louisiana Medicaid Fee for Service (FFS) Pharmacy Program and Managed Care Organizations (MCOs), in consultation with the Drug Utilization Review Board (DUR), will have a new therapeutic duplication edit at Point of Sale (POS) and clinical updates. The policy applies to pharmacy claims submitted to FFS and MCOs (Aetna, AmeriHealth Caritas, Healthy Blue, Louisiana Healthcare Connections, and UnitedHealthcare).

## **Clinical Updates**

Point of Sale edits for allergen extracts will be removed and addressed in the clinical authorization process.

The age limit for Behavioral Health Agents will be updated. The age will be modified and require behavioral health clinical authorization for 6-year-old and younger recipients at POS for Attention Deficit Hyperactivity Disorder (ADHD) stimulants and related agents, antidepressants (other and SSRIs), antipsychotics and anxiolytics.

## **Therapeutic Duplication**

A pharmacy claim for agalsidase beta (Fabrazyme<sup>®</sup>) will deny with a therapeutic duplication if there is an active claim on the recipient's file for migalastat (Galafold<sup>®</sup>). Conversely, pharmacy claims for migalastat (Galafold<sup>®</sup>) will deny with a therapeutic duplication if there is an active claim on the recipient's file for agalsidase beta (Fabrazyme<sup>®</sup>).

FFS and MCO Therapeutic Duplication for Fabrazyme® and Galafold® and Clinical Updates
December 22, 2020
Page 2

Pharmacy claims with a therapeutic duplication will have the following denial at POS:

FFS Only: NCPDP rejection code 88 (DUR reject code) mapped to

**EOB code 482** (Therapeutic Duplication-TD).

MCO Only: The pharmacy claim will deny with a **NCPDP rejection code**.

After consultation with the prescriber, the pharmacist may override the therapeutic duplication denial. This consultation is necessary to confirm that the (1) prescriber is aware of the current claim and/or (2) the addition of a second agent is necessary (i.e. change in therapy). The pharmacist may submit the following codes at POS to override the claim denial, if the prescriber deems the therapeutic duplication medically necessary:

NCPDP 439-E4 field (Reason for Service Code) TD (Therapeutic Duplication)
NCPDP 440-E5 field (Professional Service Code) MØ (Prescriber Consulted)
NCPDP 441-E6 field (Result of Service Code) 1G (Filled with Prescriber Approval)

#### **Additional Information:**

MCO Only: If additional assistance is needed, contact the health plan. (See contact information at the end of this document.)

Refer to <a href="http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf">http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf</a> for the PDL, which is inclusive of the Louisiana Uniform Prescription Drug Prior Authorization Form, medication list, and criteria.

If you have questions about the content of this memo, you may contact the FFS pharmacy help desk by phone at (800) 437-9101.

If you have questions about pharmacy claims billing, you may contact the appropriate plan at their pharmacy help desk listed in the chart below.

Healthcare Provider	Pharmacy Help Desk	Pharmacy Help Desk
		Phone Number
Aetna	CVS Health	(855) 364-2977
AmeriHealth Caritas	PerformRx	(800) 684-5502
Fee for Service	Gainwell Technologies	(800) 648-0790
Healthy Blue	CVS	(833) 236-6194
Louisiana Healthcare Connections	CVS Caremark	(800) 311-0543
UnitedHealthcare	Optum Rx	(866) 328-3108

FFS and MCO Therapeutic Duplication for Fabrazyme® and Galafold® and Clinical Updates
December 22, 2020
Page 3

Please forward this notice to other providers to assist with notification. Your continued cooperation and support of the Louisiana Medicaid Program efforts to coordinate care and improve health are greatly appreciated.

# TL/MBW/GJS

c: Healthy Louisiana Plans Melwyn B. Wendt Gainwell Technologies